Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYDY CytoDyn	$0.27 +3.5%	$0.30	$0.10 ▼ $0.49	$325.55M	1.23	1.40 million shs	1.11 million shs
JANX Janux Therapeutics	$24.97 +0.0%	$24.63	$21.97 ▼ $71.71	$1.50B	2.86	892,778 shs	907,228 shs
SDGR Schrodinger	$19.45 -2.0%	$21.24	$16.60 ▼ $28.47	$1.46B	1.67	1.23 million shs	4.40 million shs
VERA Vera Therapeutics	$21.27 -3.2%	$22.15	$18.53 ▼ $51.61	$1.40B	1.17	1.20 million shs	1.64 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYDY CytoDyn	+3.31%	+2.52%	-13.16%	-31.08%	+105.82%
JANX Janux Therapeutics	+0.04%	+10.58%	-3.07%	+2.84%	-37.84%
SDGR Schrodinger	-1.97%	+0.46%	-4.52%	-17.51%	+2.37%
VERA Vera Therapeutics	-3.19%	+7.86%	-8.32%	+0.09%	-43.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYDY CytoDyn	0.3168 of 5 stars	0.0	2.0	1.1	0.0	1.3
JANX Janux Therapeutics	2.3955 of 5 stars	3.5	3.0	2.3	1.7	0.0
SDGR Schrodinger	3.2614 of 5 stars	3.4	3.0	3.0	3.3	0.6
VERA Vera Therapeutics	3.5823 of 5 stars	4.5	3.0	1.5	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYDY CytoDyn	0.00	N/A	N/A	N/A
JANX Janux Therapeutics	3.08	Buy	$91.89	268.00% Upside
SDGR Schrodinger	2.67	Moderate Buy	$31.20	60.41% Upside
VERA Vera Therapeutics	2.90	Moderate Buy	$63.00	196.19% Upside

Current Analyst Ratings Breakdown

Latest CYDY, SDGR, JANX, and VERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	SDGR Schrodinger	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/7/2025	VERA Vera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$56.00 ➝ $53.00
8/4/2025	VERA Vera Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
6/3/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/3/2025	VERA Vera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/2/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Outperform ➝ Sector Outperform	$55.00 ➝ $65.00
6/2/2025	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $85.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYDY CytoDyn	N/A	N/A	$0.00 per share	77.91	($0.08) per share	N/A
JANX Janux Therapeutics	$10.59M	141.69	N/A	N/A	$16.48 per share	1.52
SDGR Schrodinger	$207.54M	6.88	N/A	N/A	$4.67 per share	4.16
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$7.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYDY CytoDyn	$3.74M	$0.01	26.89	∞	N/A	N/A	N/A	-4.40%	10/13/2025 (Estimated)
JANX Janux Therapeutics	-$68.99M	-$1.80	N/A	N/A	N/A	N/A	-11.48%	-11.01%	N/A
SDGR Schrodinger	-$187.12M	-$2.48	N/A	N/A	N/A	-76.22%	-45.70%	-24.81%	N/A
VERA Vera Therapeutics	-$152.15M	-$3.58	N/A	N/A	N/A	N/A	-46.70%	-39.46%	N/A

Latest CYDY, SDGR, JANX, and VERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	JANX Janux Therapeutics	-$0.48	-$0.55	-$0.07	-$0.55	$0.30 million	N/A
8/6/2025	Q2 2025	SDGR Schrodinger	-$0.83	-$0.59	+$0.24	-$0.59	$52.03 million	$54.76 million
8/5/2025	Q2 2025	VERA Vera Therapeutics	-$0.82	-$1.20	-$0.38	-$1.20	N/A	N/A
7/25/2025	Q4 2025	CYDY CytoDyn	N/A	-$0.01	N/A	-$0.01	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYDY CytoDyn	N/A	0.25	0.25
JANX Janux Therapeutics	N/A	47.03	47.03
SDGR Schrodinger	N/A	3.30	3.30
VERA Vera Therapeutics	0.16	17.03	17.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYDY CytoDyn	5.06%
JANX Janux Therapeutics	75.39%
SDGR Schrodinger	79.05%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
CYDY CytoDyn	0.54%
JANX Janux Therapeutics	8.10%
SDGR Schrodinger	21.00%
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYDY CytoDyn	20	1.25 billion	1.25 billion	Not Optionable
JANX Janux Therapeutics	30	60.09 million	55.23 million	Optionable
SDGR Schrodinger	790	73.38 million	57.97 million	Optionable
VERA Vera Therapeutics	40	63.77 million	53.38 million	Optionable

CYDY, SDGR, JANX, and VERA Headlines

Recent News About These Companies

Deutsche Bank AG Purchases 82,483 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

5 hours ago | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.00 Average Price Target from Analysts

August 12 at 2:31 AM | americanbankingnews.com

JPMorgan Chase & Co. Cuts Vera Therapeutics (NASDAQ:VERA) Price Target to $53.00

August 10, 2025 | americanbankingnews.com

Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA

August 10, 2025 | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 10, 2025 | marketbeat.com

Lifesci Capital Issues Negative Forecast for VERA Earnings

August 10, 2025 | americanbankingnews.com

FY2025 EPS Estimates for VERA Cut by Cantor Fitzgerald

August 9, 2025 | marketbeat.com

HC Wainwright Has Negative Estimate for VERA Q3 Earnings

August 9, 2025 | marketbeat.com

What is Lifesci Capital's Forecast for VERA Q3 Earnings?

August 9, 2025 | marketbeat.com

HC Wainwright Analysts Lower Earnings Estimates for VERA

August 9, 2025 | americanbankingnews.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price

August 8, 2025 | marketbeat.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 8, 2025 | globenewswire.com

Vera Therapeutics Signs New Sales Agreement with TD Securities

August 8, 2025 | theglobeandmail.com

Q3 Earnings Forecast for Vera Therapeutics Issued By Wedbush

August 8, 2025 | marketbeat.com

Vera Therapeutics (VERA) to Release Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Posts Earnings Results, Misses Estimates By $0.38 EPS

August 6, 2025 | marketbeat.com

Vera (VERA) Q2 Net Loss Widens 127%

August 6, 2025 | fool.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Down - What's Next?

August 5, 2025 | marketbeat.com

Wolfe Research Downgrades Vera Therapeutics (VERA)

August 5, 2025 | msn.com

Vera Therapeutics' (VERA) "Peer Perform" Rating Reaffirmed at Wolfe Research

August 5, 2025 | marketbeat.com

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYDY, SDGR, JANX, and VERA Company Descriptions

CytoDyn OTCMKTS:CYDY

$0.27 +0.01 (+3.47%)

As of 08/14/2025 03:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Janux Therapeutics NASDAQ:JANX

$24.97 +0.01 (+0.04%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$25.10 +0.13 (+0.52%)

As of 07:00 AM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Schrodinger NASDAQ:SDGR

$19.45 -0.39 (-1.97%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$18.74 -0.72 (-3.68%)

As of 08:09 AM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Vera Therapeutics NASDAQ:VERA

$21.27 -0.70 (-3.19%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$22.10 +0.83 (+3.88%)

As of 08:00 AM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time